{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:30:57Z","timestamp":1792791057560,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundings for Clinical Trials from Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School","award":["2022-LCYJ-PY-06"],"award-info":[{"award-number":["2022-LCYJ-PY-06"]}],"id":[{"id":"https:\/\/ror.org\/026axqv54","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90667-z","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:05:43Z","timestamp":1740096343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation"],"prefix":"10.1038","volume":"15","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuiXin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"90667_CR1","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehu028","volume":"35","author":"S Nattel","year":"2014","unstructured":"Nattel, S. et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur. Heart J. 35, 1448\u20131456. https:\/\/doi.org\/10.1093\/eurheartj\/ehu028 (2014).","journal-title":"Eur. Heart J."},{"key":"90667_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612 (2021).","journal-title":"Eur. Heart J."},{"key":"90667_CR3","doi-asserted-by":"publisher","unstructured":"Providencia, R. et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? Europace 19, 48\u201357.  https:\/\/doi.org\/10.1093\/europace\/euw080   (2017).","DOI":"10.1093\/europace\/euw080"},{"key":"90667_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamacardio.2021.0852","volume":"6","author":"MK Turagam","year":"2021","unstructured":"Turagam, M. K. et al. Assessment of Catheter ablation or antiarrhythmic drugs for first-line therapy of Atrial Fibrillation: a Meta-analysis of Randomized clinical trials. JAMA Cardiol. 6, 697\u2013705. https:\/\/doi.org\/10.1001\/jamacardio.2021.0852 (2021).","journal-title":"JAMA Cardiol."},{"key":"90667_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","volume":"114","author":"J Andrade","year":"2014","unstructured":"Andrade, J., Khairy, P., Dobrev, D. & Nattel, S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ. Res. 114, 1453\u20131468. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.303211 (2014).","journal-title":"Circ. Res."},{"key":"90667_CR6","doi-asserted-by":"publisher","first-page":"960259","DOI":"10.3389\/fcvm.2022.960259","volume":"9","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients. Front. Cardiovasc. Med. 9, 960259. https:\/\/doi.org\/10.3389\/fcvm.2022.960259 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"90667_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacep.2020.05.023","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan, E. et al. Impact of nonalcoholic fatty liver disease on Arrhythmia Recurrence following atrial fibrillation ablation. JACC Clin. Electrophysiol. 6, 1278\u20131287. https:\/\/doi.org\/10.1016\/j.jacep.2020.05.023 (2020).","journal-title":"JACC Clin. Electrophysiol."},{"key":"90667_CR8","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. S. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3 (2021).","journal-title":"Lancet"},{"key":"90667_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacasi.2023.08.003","volume":"3","author":"R Ohno","year":"2023","unstructured":"Ohno, R. et al. Association of metabolic dysfunction-associated fatty liver disease with risk of HF and AF. JACC Asia. 3, 908\u2013921. https:\/\/doi.org\/10.1016\/j.jacasi.2023.08.003 (2023).","journal-title":"JACC Asia"},{"key":"90667_CR10","doi-asserted-by":"publisher","unstructured":"Carbone, R. G. & Puppo, F. Atrial fibrillation and non-alcoholic fatty liver disease. Int. J. Cardiol. 378, 879. https:\/\/doi.org\/10.1016\/j.ijcard.2023.02.033 (2023).","DOI":"10.1016\/j.ijcard.2023.02.033"},{"key":"90667_CR11","doi-asserted-by":"publisher","first-page":"957245","DOI":"10.3389\/fendo.2022.957245","volume":"13","author":"R Decoin","year":"2022","unstructured":"Decoin, R. et al. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Front. Endocrinol. (Lausanne). 13, 957245. https:\/\/doi.org\/10.3389\/fendo.2022.957245 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"90667_CR12","doi-asserted-by":"publisher","first-page":"e008703","DOI":"10.1161\/JAHA.118.008703","volume":"7","author":"WA Huang","year":"2018","unstructured":"Huang, W. A., Dunipace, E. A., Sorg, J. M. & Vaseghi, M. Liver disease as a predictor of New-Onset atrial fibrillation. J. Am. Heart Assoc. 7, e008703. https:\/\/doi.org\/10.1161\/JAHA.118.008703 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"90667_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.mayocp.2019.08.027","volume":"95","author":"D Pastori","year":"2020","unstructured":"Pastori, D. et al. Prevalence and impact of nonalcoholic fatty liver disease in Atrial Fibrillation. Mayo Clin. Proc. 95, 513\u2013520. https:\/\/doi.org\/10.1016\/j.mayocp.2019.08.027 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"90667_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.clinre.2017.08.001","volume":"41","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha, K., Boonpheng, B., Thongprayoon, C., Jaruvongvanich, V. & Ungprasert, P. The association between non-alcoholic fatty liver disease and atrial fibrillation: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 525\u2013532. https:\/\/doi.org\/10.1016\/j.clinre.2017.08.001 (2017).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"90667_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.hrthm.2023.12.019","volume":"21","author":"S Agarwal","year":"2024","unstructured":"Agarwal, S. et al. Outcomes and readmissions in patients with nonalcoholic fatty liver disease undergoing catheter ablation for atrial fibrillation. Heart Rhythm 21, 502\u2013504. https:\/\/doi.org\/10.1016\/j.hrthm.2023.12.019 (2024).","journal-title":"Heart Rhythm"},{"key":"90667_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong, V. W., Ekstedt, M., Wong, G. L. & Hagstrom, H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 79, 842\u2013852. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036 (2023).","journal-title":"J. Hepatol."},{"key":"90667_CR17","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"key":"90667_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacasi.2023.08.013","volume":"3","author":"A Hirata","year":"2023","unstructured":"Hirata, A. & Okamura, T. New insights into the relation between metabolic dysfunction associated fatty liver disease and cardiovascular disease. JACC Asia 3, 922\u2013924. https:\/\/doi.org\/10.1016\/j.jacasi.2023.08.013 (2023).","journal-title":"JACC Asia"},{"key":"90667_CR19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0735-1097(24)03719-7","volume":"83","author":"XL Zhang","year":"2024","unstructured":"Zhang, X. L., Bao, X. & Xu, B. Association of MASLD and MAFLD with cardiovascular and mortality outcomes: a prospective study of the UK biobank cohort. J. Am. Coll. Cardiol. 83, 1729 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"90667_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee, H. H. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73, 533\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003 (2024).","journal-title":"Gut"},{"key":"90667_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","volume":"22","author":"TG Simon","year":"2023","unstructured":"Simon, T. G. et al. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study. Cardiovasc. Diabetol. 22, 343. https:\/\/doi.org\/10.1186\/s12933-023-02070-5 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"90667_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12872-024-03784-4","volume":"24","author":"Z Chen","year":"2024","unstructured":"Chen, Z., Zhang, R., Zhang, X. & Xu, W. Association between baseline glycated hemoglobin level and atrial fibrillation recurrence following cryoballoon ablation among patients with and without diabetes. BMC Cardiovasc. Disord. 24, 111. https:\/\/doi.org\/10.1186\/s12872-024-03784-4 (2024).","journal-title":"BMC Cardiovasc. Disord"},{"key":"90667_CR23","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the, L. European Association for the Study of, D. & European Association for the study of, O. EASL-EASD-EASO Clinical Practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004 (2016).","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"90667_CR24","doi-asserted-by":"publisher","unstructured":"Bedogni, G. et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 896. https:\/\/doi.org\/10.1186\/1471-230X-6-33 (2006).","DOI":"10.1186\/1471-230X-6-33"},{"key":"90667_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.003","author":"Q Zhao","year":"2023","unstructured":"Zhao, Q. & Deng, Y. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.003 (2023).","journal-title":"J. Hepatol."},{"issue":"e2110","key":"90667_CR26","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee, H., Lee, Y. H., Kim, S. U. & Kim, H. C. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a Nationwide Cohort Study. Clin. Gastroenterol. Hepatol. 19(e2110), 2138\u20132147. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"90667_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01038-6","author":"D Bode","year":"2024","unstructured":"Bode, D., Pronto, J. R. D., Schiattarella, G. G. & Voigt, N. Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications. Nat. Rev. Cardiol. https:\/\/doi.org\/10.1038\/s41569-024-01038-6 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"90667_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141, 1227\u20131234. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044183 (2020).","journal-title":"Circulation"},{"key":"90667_CR29","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","volume":"9","author":"MR Abu-Qaoud","year":"2023","unstructured":"Abu-Qaoud, M. R. et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin. Electrophysiol. 9, 2109\u20132118. https:\/\/doi.org\/10.1016\/j.jacep.2023.06.008 (2023).","journal-title":"JACC Clin. Electrophysiol."},{"key":"90667_CR30","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143, e984\u2013e1010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973 (2021).","journal-title":"Circulation"},{"key":"90667_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","volume":"20","author":"GF Romiti","year":"2022","unstructured":"Romiti, G. F. et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 20, 326. https:\/\/doi.org\/10.1186\/s12916-022-02526-7 (2022).","journal-title":"BMC Med."},{"key":"90667_CR32","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCRESAHA.121.319059","volume":"128","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Nonalcoholic fatty liver disease: an emerging driver of Cardiac Arrhythmia. Circ. Res. 128, 1747\u20131765. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319059 (2021).","journal-title":"Circ. Res."},{"key":"90667_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044","volume":"39","author":"A Mantovani","year":"2019","unstructured":"Mantovani, A. et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 39, 758\u2013769. https:\/\/doi.org\/10.1111\/liv.14044 (2019).","journal-title":"Liver Int."},{"key":"90667_CR34","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1038\/s41598-020-61750-4","volume":"10","author":"HE Park","year":"2020","unstructured":"Park, H. E., Lee, H., Choi, S. Y., Kim, H. S. & Chung, G. E. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index. Sci. Rep. 10, 5023. https:\/\/doi.org\/10.1038\/s41598-020-61750-4 (2020).","journal-title":"Sci. Rep."},{"key":"90667_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jhep.2022.05.030","volume":"77","author":"LA van Kleef","year":"2022","unstructured":"van Kleef, L. A. et al. Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study. J. Hepatol. 77, 931\u2013938. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.030 (2022).","journal-title":"J. Hepatol."},{"key":"90667_CR36","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","volume":"37","author":"S Ballestri","year":"2020","unstructured":"Ballestri, S. et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv. Ther. 37, 1910\u20131932. https:\/\/doi.org\/10.1007\/s12325-020-01307-z (2020).","journal-title":"Adv. Ther."},{"key":"90667_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41569-020-00451-x","volume":"18","author":"R Parameswaran","year":"2021","unstructured":"Parameswaran, R., Al-Kaisey, A. M. & Kalman, J. M. Catheter ablation for atrial fibrillation: current indications and evolving technologies. Nat. Rev. Cardiol. 18, 210\u2013225. https:\/\/doi.org\/10.1038\/s41569-020-00451-x (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"90667_CR38","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMoa2307291","volume":"389","author":"VY Reddy","year":"2023","unstructured":"Reddy, V. Y. et al. Pulsed field or conventional thermal ablation for Paroxysmal Atrial Fibrillation. N. Engl. J. Med. 389, 1660\u20131671. https:\/\/doi.org\/10.1056\/NEJMoa2307291 (2023).","journal-title":"N. Engl. J. Med."},{"key":"90667_CR39","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1161\/CIRCULATIONAHA.123.063988","volume":"147","author":"A Verma","year":"2023","unstructured":"Verma, A. et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation 147, 1422\u20131432. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063988 (2023).","journal-title":"Circulation"},{"key":"90667_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl. J. Med. 390, 497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000 (2024).","journal-title":"N Engl. J. Med."},{"key":"90667_CR41","doi-asserted-by":"publisher","unstructured":"Loomba, R. et al. Controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl. J. Med. 389, 998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286 (2023). Randomized.","DOI":"10.1056\/NEJMoa2304286"},{"key":"90667_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosi. N Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2401943 (2024).","journal-title":"N Engl. J. Med."},{"key":"90667_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A. J. et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2401755 (2024).","journal-title":"N Engl. J. Med."},{"issue":"e222","key":"90667_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cgh.2020.11.028","volume":"20","author":"GS Jones","year":"2022","unstructured":"Jones, G. S., Alvarez, C. S., Graubard, B. I. & McGlynn, K. A. Agreement between the prevalence of nonalcoholic fatty liver Disease determined by transient elastography and fatty liver indices. Clin. Gastroenterol. Hepatol. 20(e222), 227\u2013229. https:\/\/doi.org\/10.1016\/j.cgh.2020.11.028 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"90667_CR45","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","volume":"11","author":"EM Koehler","year":"2013","unstructured":"Koehler, E. M. et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin. Gastroenterol. Hepatol. 11, 1201\u20131204. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.031 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90667-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:05:50Z","timestamp":1740096350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90667-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90667"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90667-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research was approved by the Ethics Committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. Each patient has signed an informed consent before enrolling into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"6287"}}